XBiotech's Vilamakitug Advances to Phase II for Spondyloarthritis After FDA Clearance
Summary
XBiotech has launched a Phase II clinical trial for its drug, vilamakitug, targeting active axial spondyloarthritis. The Investigational New Drug (IND) application for the V-SPINE study successfully cleared FDA review without a clinical hold, allowing patient enrollment in the United States. This is a significant step for the small-cap biopharmaceutical company, marking the resumption of its rheumatology program and advancing a potential treatment for an unmet medical need. The study will enroll 150 participants, with results from this trial being critical for the drug's future development.
At the time of this announcement, XBIT was trading at $2.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $71.3M. The 52-week trading range was $2.09 to $3.61. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.